Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan;78(2):447-467.
doi: 10.1007/s00018-020-03600-0. Epub 2020 Jul 22.

Functional heterogeneity of mesenchymal stem cells from natural niches to culture conditions: implications for further clinical uses

Affiliations
Review

Functional heterogeneity of mesenchymal stem cells from natural niches to culture conditions: implications for further clinical uses

Luis A Costa et al. Cell Mol Life Sci. 2021 Jan.

Abstract

Mesenchymal stem cells (MSC) are present in all organs and tissues. Several studies have shown the therapeutic potential effect of MSC or their derived products. However, the functional heterogeneity of MSC constitutes an important barrier for transferring these capabilities to the clinic. MSC heterogeneity depends on their origin (biological niche) or the conditions of potential donors (age, diseases or unknown factors). It is accepted that many culture conditions of the artificial niche to which they are subjected, such as O2 tension, substrate and extracellular matrix cues, inflammatory stimuli or genetic manipulations can influence their resulting phenotype. Therefore, to attain a more personalized and precise medicine, a correct selection of MSC is mandatory, based on their functional potential, as well as the need to integrate all the existing information to achieve an optimal improvement of MSC features in the artificial niche.

Keywords: Aging diseases; Conditioned medium; Diabetes; Exosomes; Extracellular vesicles; Lupus; Regenerative medicine; Secretome.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following competing interests: F.J.V and N.E are co-inventors of a patent (“Human uterine cervical stem cell population and uses thereof”) owned by GiStem Research, of which L.A.C, N.E, L.O.G, J.S, P.P J.S. and F.J.V are shareholders. The funding sponsors had no role in the design of this review, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.

Figures

Fig. 1
Fig. 1
Schematic representation of MSC heterogeneity in their different niches and factors that could influence their fate
Fig. 2
Fig. 2
Factors related to modifiable culture conditions which may influence the quality of MSC to obtain tailor-made secretome-derived products (paracrine factors, microvesicles or exosomes)

References

    1. Samsonraj RM, Raghunath M, Nurcombe V, Hui JH, van Wijnen AJ, Cool SM. Concise review: multifaceted characterization of human mesenchymal stem cells for use in regenerative medicine. Stem Cells Transl Med. 2017;12(6):2173–2185. - PMC - PubMed
    1. Vizoso FJ, Eiro N, Costa L, Esparza P, Landin M, Diaz-Rodriguez P, Schneider J, Perez-Fernandez R. Mesenchymal stem cells in homeostasis and systemic diseases: hypothesis, evidences, and therapeutic opportunities. Int J Mol Sci. 2019;15(20):3738. - PMC - PubMed
    1. Lalu MM, Sullivan KJ, Mei SH, Moher D, Straus A, Fergusson DA, Stewart DJ. Evaluating mesenchymal stem cell therapy for sepsis with preclinical meta-analyses prior to initiating a first-in-human trial. Elife. 2016;5:e17850. - PMC - PubMed
    1. McIntyre LA, Moher D, Fergusson DA, Sullivan KJ, Mei SH, Lalu M, Marshall J, McLeod M, Griffin G, Grimshaw J, Turgeon A, Avey MT, Rudnicki MA, Jazi M, Fishman J, Stewart DJ. Efficacy of mesenchymal stromal cell therapy for acute lung injury in preclinical animal models: a systematic review. PLoS One. 2016;1(11):e0147170. - PMC - PubMed
    1. He F. Mesenchymal stem cell therapy for paraquat poisoning: a systematic review and meta-analysis of preclinical studies. Stem cells (Dayton, Ohio) 2018;3(13):e0194748. - PMC - PubMed

MeSH terms

LinkOut - more resources